Literature DB >> 30060721

Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus.

L Mu1, Y Hao1, Y Fan1, H Huang1, X Yang1, A Xie1, X Zhang1, L Ji1, Y Geng1, Z Zhang1.   

Abstract

Objectives To investigate the mortality and causes of death in Chinese patients with systemic lupus erythematosus. Methods We collected the clinical data of all consecutive adult systemic lupus erythematosus patients at the Rheumatology department of Peking University First Hospital between January 2007 and December 2015. The primary causes of death were identified, the standardized mortality ratio and years of life lost were calculated, and the survival and variables associated with mortality were determined by Kaplan-Meier and Cox regression analysis respectively. Results The mean age of all 911 patients (814 females and 97 males) was 37.8 ± 14.7 years, the median disease duration at recruitment was 2.6 (0.5-7.0) years, and the median follow-up duration was 3.0 (1.4-5.1) years. Among the 911 patients who were successfully followed up, 45 patients died. Infection (31.1%) was the leading cause of death followed by renal failure, pulmonary arterial hypertension and cerebrovascular diseases. The overall age and sex-adjusted standardized mortality ratio was 3.2 (95% confidence interval 2.4-4.0), and the years of life lost for women and men were 29.8 and 9.4 respectively. Overall survival at 1, 5 and 10 years was 98.2%, 95.3% and 93.7% respectively. Older age at disease onset, infection, autoimmune hemolytic anemia, thrombocytopenia and pulmonary arterial hypertension were independent risk factors for the mortality of systemic lupus erythematosus patients, and longer disease duration at recruitment was an independent protective factor. Conclusions Mortality of systemic lupus erythematosus patients in China was substantial, especially in females, with infection the leading cause of death. Older age at disease onset, infection, autoimmune hemolytic anemia, thrombocytopenia and pulmonary arterial hypertension were associated with poor outcomes.

Entities:  

Keywords:  Causes of death; mortality; survival; systemic lupus erythematosus

Mesh:

Year:  2018        PMID: 30060721     DOI: 10.1177/0961203318789788

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus.

Authors:  Yoosuf Ali Ashraf Muhammad Hussenbocus; Ziyi Jin; Wenyou Pan; Lin Liu; Min Wu; Huaixia Hu; Xiang Ding; Hua Wei; Yaohong Zou; Xian Qian; Meimei Wang; Jian Wu; Juan Tao; Jun Tan; Zhanyun Da; Miaojia Zhang; Jing Li; Xuebing Feng; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2022-03-01       Impact factor: 2.980

2.  In-hospital mortality in patients with systemic lupus erythematosus: a study from Jordan 2002-2017.

Authors:  Marwan H Adwan; Ula Qasem; Khader N Mustafa
Journal:  Rheumatol Int       Date:  2020-03-07       Impact factor: 2.631

3.  Mesenchymal Stem Cells Enhance Pulmonary Antimicrobial Immunity and Prevent Following Bacterial Infection.

Authors:  Wenchao Li; Weiwei Chen; Saisai Huang; Xiaojun Tang; Genhong Yao; Lingyun Sun
Journal:  Stem Cells Int       Date:  2020-03-28       Impact factor: 5.443

4.  Mortality risk prediction in lupus patients complicated with invasive infection in the emergency department: LUPHAS score.

Authors:  Wanlong Wu; Jun Ma; Yuhong Zhou; Chao Tang; Feng Zhao; Fangfang Sun; Wenwen Xu; Jie Chen; Shuang Ye; Yi Chen
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-11-05       Impact factor: 5.346

5.  Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.

Authors:  Yanjie Hao; Shereen Oon; Lanlan Ji; Dai Gao; Yong Fan; Yan Geng; Xiaohui Zhang; Guangtao Li; Eric F Morand; Mandana Nikpour; ZhuoLi Zhang
Journal:  Clin Rheumatol       Date:  2021-09-30       Impact factor: 2.980

6.  Mortality in Inflammatory Rheumatic Diseases: Lithuanian National Registry Data and Systematic Review.

Authors:  Jolanta Dadonienė; Greta Charukevič; Gabija Jasionytė; Karolina Staškuvienė; Dalia Miltinienė
Journal:  Int J Environ Res Public Health       Date:  2021-11-24       Impact factor: 3.390

7.  Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.

Authors:  Yanjie Hao; Lanlan Ji; Dai Gao; Yong Fan; Yan Geng; Xiaohui Zhang; Guangtao Li; Zhuoli Zhang
Journal:  Lupus Sci Med       Date:  2022-03

Review 8.  Total Glucosides of Paeonia lactiflora for Safely Reducing Disease Activity in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Authors:  Yifan Chen; Liuding Wang; Yu Cao; Nannan Li
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

9.  Inpatient mortality in transition-aged youth with rheumatic disease: an analysis of the National Inpatient Sample.

Authors:  Paul T Jensen; Keumseok Koh; Rebecca E Cash; Stacy P Ardoin; Ayaz Hyder
Journal:  Pediatr Rheumatol Online J       Date:  2020-03-30       Impact factor: 3.054

10.  Autoantibody clustering of lupus-associated pulmonary hypertension.

Authors:  Marisa Mizus; Jessica Li; Daniel Goldman; Michelle A Petri
Journal:  Lupus Sci Med       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.